-

WellAir Announces Appointment of Brad Niemann as Executive Vice President of Healthcare

DUBLIN & STAMFORD, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--WellAir, a leader in delivering clean air solutions to people around the world, today announced the appointment of Brad Niemann as Executive Vice President of Healthcare, to help drive the Company’s commercial growth within the global healthcare sector.

"We are pleased to have Brad join our leadership team as we continue to strengthen our commercial and business strategies within healthcare,” said Todd M. Pope, President and Chief Executive Officer at WellAir. “His extensive experience in addressing opportunities across the healthcare landscape will enable our team to better invest, innovate and support our healthcare customers as a leading provider of clean air and surface disinfection solutions in the industry.”

Mr. Niemann brings nearly 20 years of extensive executive management experience in the medical device industry. Previously he held multiple leadership positions at Orthofix International N.V, a global medical device company focused on musculoskeletal products and therapies. He joined Orthofix in 2012 as Senior Vice President, Commercial Operations. He was promoted to President, BioStim in 2013 and to President of Global Orthofix Spine in 2018. Prior to Orthofix, Mr. Niemann has also held several management and leadership roles at DJO Global, Inc. including Senior Vice President, Recovery Sciences where he led their commercial efforts.

"I am thrilled to support the continued growth of WellAir as a leading healthcare company," said Brad Niemann, Executive Vice President, Healthcare at WellAir. "Our recent Defend 1050 510 (k) Class II clearance from the FDA in January 2021 is an important milestone as we continue to launch new healthcare products based on our differentiated technology. Our healthcare focus ensures that we continue to provide innovative solutions addressing the critical role of clean air and surfaces in these environments.”

About WellAir

WellAir’s mission is to make the indoor world cleaner and safer. It’s that important. Our products are scientifically proven and harmonize how we work, live and play.

WellAir, headquartered in Dublin, Ireland, with offices in Stamford, Connecticut, and Research Triangle Park, North Carolina, is a leading provider of infection control solutions. The group operates through its core business brands, Novaerus, Plasma Air, and NuvaWave. We reach our customers through multiple channels; this diversity lets them benefit from our broad range of solutions.

Contacts

Cindy Caserta
WellAir
ccaserta@wellairsolutions.com
203-451-3131

Renee Volpini
Westwicke/ICR
Renee.Volpini@westwicke.com
917-923-8117

WellAir


Release Versions

Contacts

Cindy Caserta
WellAir
ccaserta@wellairsolutions.com
203-451-3131

Renee Volpini
Westwicke/ICR
Renee.Volpini@westwicke.com
917-923-8117

More News From WellAir

WellAir Announces Appointment of Kieran Hannon as Chief Marketing Officer

DUBLIN & STAMFORD, Conn. & CARY, N.C.--(BUSINESS WIRE)--WellAir, a leader in delivering clean air solutions to people around the world, today announced the appointment of Kieran Hannon as Chief Marketing Officer as the Company enters its next phase of growth. "Kieran is a globally recognized, creative and innovative business strategist. His expertise will be a valuable complement to our leadership team and a driving force in the expansion of the WellAir brand as we continue to advance our air c...

WellAir Announces Acquisition of UV Innovators

DUBLIN & CARY, N.C.--(BUSINESS WIRE)--WellAir, a leader in delivering clean air solutions to people around the world, today announced the acquisition of UV Innovators (“UVI”), a North Carolina-based developer of medical-grade handheld UVC disinfection technology. In addition, the company announced that Todd M. Pope, executive chairman of UV Innovators, has been appointed President and CEO of WellAir. Creating an Industry Leading Disinfection Platform WellAir’s mission is to mitigate airborne pa...

Novaerus Defend 1050 Cleared by FDA as 510(k) Class II Medical Device to Inactivate and Filter Out Airborne Virus and Bacteria for Medical Purposes

DUBLIN & STAMFORD, Conn.--(BUSINESS WIRE)--Novaerus, a WellAir company that delivers clean air solutions to help prevent the spread of infectious outbreaks, announced today that the U.S. Food and Drug Administration (FDA) cleared the Novaerus Defend 1050 (NV 1050) as a 510(k) Class II Medical Device to inactivate and filter out micro-organisms, including virus and bacteria, for medical purposes. The Novaerus Defend 1050 is the first system that uses NanoStrike®, a patented plasma generating tec...
Back to Newsroom